1	Unexpected Increase in Postoperative Atrial Fibrillation by Calcium-				
2	mediated Autonomic Denervation:				
3	Results of the CAP-AF2 Trial				
4	Huishan Wang, MD ¹ *; Yuji Zhang, MD ¹ *; Fangran Xin, PhD ¹ ; Jikai Zhao, MD ¹ ; Keyan Zhao,				
5	MD ¹ ; Dengshun Tao, MD ¹ ; Praloy Chakraborty, MD ² ; Zongtao Yin, MD ¹ ; Guannan Liu, MD ¹ ;				
6	Sunny S. Po, MD, PhD ²				
7	1. Department of Cardiovascular Surgery, General Hospital of Northern Theater Command,				
8	Shenyang, Liaoning, China				
9	2. Section of Cardiovascular Diseases and Heart Rhythm Institute, University of Oklahoma				
10	Health Sciences Center, Oklahoma City, OK, USA				
11	*: These authors contributed equally				
12					
13	Word Count: 3815				
14	Short Title: denervation increased postoperative atrial fibrillation				
15	Key Words:				
16 17	Autonomic nervous system, autonomic denervation, ganglionated plexi, postoperative atrial fibrillation,				
18					
19	Corresponding Author:				
20	Sunny S. Po, MD, PhD				
21	Section of Cardiovascular Diseases and Heart Rhythm Institute				
22	University of Oklahoma Health Sciences Center				
23	800 Stanton L. Young Blvd. Suite 5400, Oklahoma City, Oklahoma, USA				
24	E-mail: <u>sunny-po@ouhsc.edu</u> Telephone: 405-271-9696 Fax: 405-271-7455				
25					

26 ABSTRACT

Background In the CAP-AF trial, injection of calcium chloride (CaCl₂) into the four major atrial 27 ganglionated plexi (GP) reduced the relative risk of postoperative atrial fibrillation (POAF) by 28 63% in patients undergoing coronary artery bypass surgery (CABG). 29 30 **Objective.** The CAP-AF2 trial intended to investigate if similar autonomic denervation could prevent POAF in patients with mitral regurgitation (MR) but without persistent AF who 31 underwent surgery for MR. 32 33 Methods The CAP-AF-2 trial was an investigator-initiated, single center, double-blind, randomized clinical trial. This trial planned to 1:1 randomize 320 adult patients to CaCl₂ vs. 34 sodium chloride (NaCl, sham) injection into the four GP during surgery. The primary outcome 35 was incidence of POAF (≥30 seconds) in 7 days. Secondary outcomes included length of 36 hospitalization, POAF burden, actionable antiarrhythmic therapy for POAF, heart rate variability 37 changes and plasma inflammatory markers. 38 Results This trial was terminated after midterm analysis showing that the cumulative POAF 39 incidence was higher in the CaCl₂ group (43/78, 55.13%) than the NaCl group (31/82, 37.80%; 40 41 confidence interval of difference 1.01%-32.48%, P=0.028). In the CaCl₂ group, more patients were hospitalized over 7 days (69.8% vs. 45.2%; p=0.033) and more patients required 42 amiodarone therapy (p=0.039). AF burden, plasma inflammatory markers and heart rate 43 variability were not different between the two groups. Frequent atrial bigeminy or nonsustained 44 atrial tachycardia immediately preceded POAF in 76.7% (CaCl₂) and 29.0% (NaCl) patients, 45 respectively (P<0.001), consistent with triggers caused by higher sympathetic activity. 46 Immunohistochemistry study obtained from GP and left atrium during surgery revealed 47 parasympathetic dominance in patients receiving MV surgery but sympathetic dominance in 48 patients undergoing CABG. 49

50

51	Conclusions Unlike patients undergoing CABG, autonomic denervation increased the risk of
52	POAF in patients receiving MR surgery, indicating distinct AF substrate in different
53	cardiovascular diseases. Calcium-mediated autonomic denervation may have tipped the tissue
54	autonomic balance toward sympathetic dominance and provided triggers for POAF. While
55	autonomic denervation has emerged as a novel therapy to treat various cardiovascular diseases, it
56	should only be performed with evidence supported by randomized clinical trials.
57	The Chinese Clinical Trial Registry registration number: ChiCTR2000029314.
58	website: http://www.chictr.org.cn/showproj.aspx?proj=48587

60 CLINICAL PERSPECTIVES:

61 What is new:

62	- Calcium-mediated autonomic denervation increased the incidence of post-operative
63	atrial fibrillation (AF) in patient undergoing mitral valve surgery for severe mitral
64	regurgitation, contradictory to the beneficial effects it exerted on patients undergoing
65	coronary artery bypass surgery.
66	Clinical implications:
67	- Each cardiovascular disease may have its distinct autonomic balance at the tissue level.
68	- Mechanisms underlying the initiation and maintenance of AF vary greatly among
69	cardiovascular diseases; autonomic denervation therefore can be beneficial or
70	harmful.
71	- Autonomic denervation for each cardiovascular disease should only be performed with
72	evidence from randomized clinical trials to demonstrate its efficacy and safety.
73	
74	

75

- 76 Abbreviations:
- 77 ANS: autonomic nervous system
- 78 CABG: coronary artery bypass grafting
- 79 CaCl₂: calcium chloride
- 80 ChAT: choline acetyltransferase
- 81 GP: ganglionated plexi
- 82 MV: mitral valve
- 83 NaCl: sodium chloride
- 84 POAF: postoperative atrial fibrillation
- 85 TH: tyrosine hydroxylase

87 INTRODUCTION

88	Postoperative atrial fibrillation (POAF) is one of the most common complications of
89	cardiac surgery and is a multifactorial disease. ^{1,2} Contributing factors include sympathetic surge,
90	intense inflammation, oxidative stress and preexisting atrial diseases. Despite the use of β -
91	blockers and amiodarone, the incidence of POAF remains high. ³⁻⁵
92	Ganglionated plexi (GP), embedded in epicardial fat pads, are widely considered as the
93	"integration centers" of the extensive neural network formed by the intrinsic cardiac autonomic
94	nervous system (ANS). ⁶⁻⁹ GP contain both sympathetic and parasympathetic neural elements.
95	Preclinical and clinical studies demonstrated that simultaneous or sequential activation of cardiac
96	parasympathetic and sympathetic systems preceded AF initiation. ¹⁰⁻¹² The four major atrial GP
97	adjacent to pulmonary veins (PV) are particularly important in AF initiation and
98	maintenance. ^{13,14} Circumferential PV isolation transects at least 3 of the 4 major atrial GP.
99	Autonomic denervation therefore has been proposed to play an important role in the success of
100	AF ablation. ^{15,16}
101	It is known that excessive intracellular Ca ²⁺ concentration can be lethal to neurons. ^{17,18}
102	In the CAP-AF (<u>Calcium-mediated</u> <u>A</u> utonomic Denervation in <u>P</u> ostoperative <u>A</u> trial <u>F</u> ibrillation)
103	trial, we demonstrated that calcium-mediated neurotoxicity by injecting calcium chloride (CaCl ₂)
104	into the four major atrial GP reduced the incidence of POAF by 63% as compared to the sham
105	injection sodium chloride (NaCl) in patients undergoing coronary artery bypass grafting surgery
106	(CABG). ¹⁹ We hypothesized that the substrate of POAF and the role of ANS may be distinct
107	among patients with different cardiovascular diseases. The CAP-AF2 trial was designed to
108	investigate if Ca-mediated autonomic denervation could prevent POAF in patients with mitral
109	regurgitation (MR) without persistent AF who underwent mitral valve (MV) replacement or
110	repair.

111 METHODS

112 Trial Design and oversight

The Calcium-mediated Autonomic Denervation in Postoperative Atrial Fibrillation-2 113 (CAP-AF2) trial is a single-center, sham-controlled, double-blind, randomized clinical trial that 114 was conducted in accordance with the principles of the Declaration of Helsinki and the 115 International Conference on Harmonization Good Clinical Practice Guideline. The protocol was 116 approved by the Ethics Committee of the General Hospital of Northern Theater Command and 117 registered in the Chinese Clinical Trial Registry (registration number: ChiCTR2000029314; 118 website: http://www.chictr.org.cn/showproj.aspx?proj=48587). The trial was overseen by the Ethics 119 Committee and the Science Discipline Department. Both committees had the authority to stop 120 the trial for safety or efficacy concerns. All patients enrolled into this trial gave informed consent 121 for participation. 122 The primary outcome is the incidence of POAF in the first 7 days after surgery.¹⁹ POAF 123 was defined as any atrial tachyarrhythmia episode⁵ lasting \geq 30 seconds following surgery.¹⁹ 124 Secondary outcomes include length of hospitalization following surgery, AF burden during the 125 first 7 postoperative days, average ventricular rate during AF, percentage of patients with AF 126 lasting > 24 or 48 hours, actionable antiarrhythmic therapy to treat POAF, frequency of 127 premature atrial contractions (PACs) as well as plasma level of inflammatory markers including 128 interleukin-6 (IL-6) and high sensitivity c-reactive protein (hsCRP). 129 **Patient Population** 130

Adult patients referred for isolated MV repair or replacement for MR were eligible for enrollment. Exclusion criteria included: (1) adult patients >80 years of age, (2) history of persistent AF or persistent AF detected by 7-day Holter monitoring before surgery, (3) prior cardiac surgery, 4) poor compliance or inability to complete follow-up, (5) urgent cardiac surgery, (6) congenital heart disease, (7) significant mitral stenosis (MV orifice area <2 cm²), (8)

136	concomitant surgery of any kind, (9) abnormal liver or kidney function >3x upper normal limit,	
137	(10) diseases requiring radiotherapy, chemotherapy or long-term hormone treatment, (11)	
138	ejection fraction <40%, (12) taking class I or III antiarrhythmic agents before surgery, (13)	
139	significant left atrial enlargement (>5 cm), (14) concomitant AF ablation, (15) participating in	
140	another clinical trial and (16) refusal to enrollment.	
141	Sample Size Calculation and Randomization	
142	We assumed a 40% incidence of POAF in the NaCl group based on the historical POAF	
143	incidence in the study center. We determined the enrollment of 152 CaCl_2 patients and 152	
144	NaCl patients would provide a power of at least 80% to detect a 15% absolute reduction in the	
145	incidence of POAF in the CaCl ₂ group compared to the NaCl (sham) group with a two-sided	
146	type-I error rate of 0.05. We expected a 5% drop-out rate; each group will therefore require 160	
147	patients.	
148	Eligible patients were randomly assigned to either the CaCl ₂ group or NaCl group by	

means of a computer-generated randomization system with a block of 8 with the group 149 assignment concealed. CaCl₂ or NaCl solution was prepared in a syringe accordingly. The 150 surgery staff as well as the personnel involving post-operative care, clinical data collection and 151

outcome assessment were blinded to randomization.

153 **Preoperative baseline data collection**

Prior to surgery, all patients with severe MR referred for MV surgery received 7-day 154 Holter monitoring with the capability of heart rate variability calculation.¹⁹ Patients with a 155 history of persistent AF or had AF for \geq 7 days preoperatively were excluded from this study. 156 The rest of the patients meeting the inclusion criteria were considered potential candidates. 157

158 Intervention

152

After MV repair or replacement, operators performed multi-point injection of 2 mL of 159 5% CaCl₂ or 0.9% NaCl into the four major atrial GP as previously described.¹⁹ All the surgeons 160

161	were already familiar with the location of the four major atrial GP from the CAP-AF trial. The
162	anterior right GP is located near the annular aspect of the right superior PV-atrial junction; the
163	inferior right GP at the inferior-posterior LA, below the right inferior PV. ^{15,19} The superior left
164	GP is situated near the junction of the left superior PV, left atrium (LA) and left pulmonary
165	artery; the inferior left GP at the inferior-posterior LA below the left inferior PV.
166	Outcome Measures
167	Continuous telemetry monitoring and 7-day Holter monitoring ensued after surgery.
168	Continuous heart rate variability (HRV) was measured for 7 days following surgery. If AF \geq 30
169	seconds was detected by any of the three modalities, it was considered a POAF event: (1) routine
170	12-lead ECG, (2) continuous telemetry monitoring with full-disclosure until discharge and (3) 7-
171	day Holter monitoring equipped with an automated algorithm for detection of AF onset and
172	duration as well as PACs and nonsustained atrial tachycardia as previously described (Yueguang
173	Medical Technologies, Shanghai, China). ¹⁹ POAF events were adjudicated by physicians who
174	were blinded to randomization. AF burden was defined as the sum of the duration of all episodes
175	of AF during the 7-day period after surgery. The standard practice to treat POAF in the study
176	center was to initiate amiodarone therapy after AF sustained \geq 30 minutes or AF caused
177	hemodynamic concerns. In the presence of myocardial ischemia or hemodynamic compromise,
178	POAF was treated with cardioversion or intravenous esmolol infusion, in addition to amiodarone
179	therapy. Inflammatory markers including hsCRP and IL-6 were measured on postoperative day 1
180	and 3.
181	Surgical specimen acquisition and immunohistochemistry
182	After midterm analysis, to better understand the mechanisms underlying the contradictory

effect of Ca^{2+} -mediated autonomic denervation, 113 consecutive patients referred for CABG or

184 MV surgery were screened. Forty patients meet the inclusion criteria of the CAPF-AF or CAP-

AF2 trial (CABG, n=20; MV surgery, n=20) gave consent to allow investigators to take tissue

186 samples (average $0.5 \times 0.5 \text{ cm}^2$) in the anterior right GP and adjacent myocardium (**Online** 187 **Table**). The samples were divided into two parts. One part of the samples was fixed in 4% 188 paraformaldehyde for 4 hours and embedded in paraffin; sections were performed longitudinally 189 and cut every 5 µm. The other part was frozen at -80°C for subsequent molecular biological 190 assays.

- **191** Immunohistochemistry studies
- 192 Immunohistochemistry of tyrosine hydroxylase (TH) and choline acetyltransferase (ChAT)
- 193 was performed as previously describe.²⁰ Image analysis of nerve density and
- 194 immunohistochemistry staining was detected via ImageJ (Rawak Software Inc., Stuttgart,
- 195 Germany). Quantitative analysis of the TH and ChAT expression in myocardial and ARGP
- 196 samples was determined by ELISA and Western blot as described before.²⁰

197 Statistical Analysis

All analyses were based on the intention-to-treat principle including all patients who were 198 199 randomized. For the primary outcome, Kaplan-Meier survival curves were used to describe the time-dependent incidence of POAF of both groups, the difference of which was compared by the 200 log-rank test. Secondary outcomes were evaluated by Mann-Whitney U test, Chi-square test or 201 202 Fisher's exact test. Data were reported as medians and quartiles (1st, 3rd quartile) for quantitative data and as numbers for qualitative data. For the heart rate variability (HRV) data 203 requiring repeated measures, generalized estimating equations were used to test possible 204 differences in HRV, assuming treatment and time since surgery as fixed factors, with marginal 205 206 distribution and a first-order autoregressive correlation matrix to test the main and interaction 207 effects. All analyses were conducted using the SPSS software (version 24.0) and R software version 4.1.3. All reported P values are two-sided; significant level is 0.05. P values and 95% 208 209 confidence intervals presented in this report have not been adjusted for multiplicity; therefore, 210 inferences drawn from these statistics should be interpreted with caution.

211

212 **RESULTS**

213	Between November 1, 2020 and March 29, 2022, 884 patients were referred to the
214	General Hospital of Northern Theater Command for surgery to treat severe MR. A total of 160
215	patients, who met the inclusion criteria and gave consents, were randomized to the CaCl ₂ group
216	(N=78) and NaCl group (N=82) before the midterm analysis (Figure 1A). Baseline
217	characteristics were not different between the two groups (Table 1). Three of 78 patients in the
218	CaCl ₂ group and 2 of 82 patients in the NaCl group had paroxysmal AF based on history and 7-
219	day Holter monitoring before surgery.
220	No patient received other pharmacological prophylaxis for POAF. All patients underwent
221	successful surgeries for MV replacement or repair as previously described. ²¹ Thirty-six and 45
222	patients underwent MV repair in the CaCl ₂ group and NaCl group, respectively. The rest of the
223	patients received MV replacement. Under direct vision, 2 mL of CaCl ₂ or NaCl was injected into
224	each of the 4 major atrial GP in all 160 patients as described previously. ¹⁹ Injection of 4 GP took
225	approximately 10 minutes. CaCl ₂ solution leak was quickly removed by suction to prevent
226	possible injury to the surrounding tissue. After injection, the pericardial space was irrigated with
227	saline before closure.

228 **Primary Outcome:**

229 Midterm analysis revealed that the POAF incidence was higher in the CaCl₂ group 230 (55.13%) than that in the NaCl group (37.80%; see results below). The research oversight 231 committee determined that CaCl₂ injection caused harm and terminated the trial. All the analyses 232 therefore only included the 160 patients enrolled prior to the midterm analysis (78 and 82 233 patients in the CaCl₂ and NaCl group, respectively). All 160 patients stayed in the hospital for \geq 7 234 days; there was no missing data. POAF occurred during the first 7 days after surgery in 31 of 82

patients (37.80%) in the NaCl group and 43 of 78 patients (55.13%) in the CaCl₂ group (95%)

confidence interval of difference: 1.01%-32.48%, P=0.028) (Figure 1B). The Kaplan-Meier curve also illustrates separation of the two curves on postoperative day 3 when the occurrence of POAF typically reaches its peak (Figure 1C). The median of the first episode of POAF occurred 37.3 (28.1, 48.9) hours after surgery in the NaCl group and 41.5 hours (33.0, 56.9) in the CaCl₂ group (P=0.132). All patients with AF received subcutaneous enoxaparin injection until discharge.

242 Secondary Outcomes and AF-related measurements

The median length of hospitalization and ICU stay were not different between the two 243 groups (Table 2). When POAF occurred, more patients in the CaCl₂ group were hospitalized >7244 245 days after surgery (69.8% vs. 45.2%, P=0.033). Patients in the CaCl₂ group had more episodes of POAF (p=0.007) but with similar AF burden. The average ventricular rate in POAF as well as 246 247 the number of patients with POAF>24 hours or >48 hours were not different between the two 248 groups, either. More patients in the CaCl₂ group required amiodarone to treat POAF, which was determined by clinicians when POAF lasted longer than 30 minutes. Plasma levels of hs-CRP 249 and IL-6 on postoperative day 1 and 3 were not different between the two groups. Two patients 250 251 in each group required cardioversion for hemodynamic compromise. The time-domain measurements as well as the frequency domain measurements of HRV such as low frequency 252 (LF) power, high frequency (HF) power and the LF/HF ratio were not different between the two 253 groups (Online Figure 1). The frequency of PACs, couplets and nonsustained atrial tachycardia 254 255 was not different between the two groups on each postoperative day (**Online Figure 2**) as well.

256 Adverse effects and complications

To prevent adverse effects such as significant bradycardia (heart rate <40 bpm) as
described in the CAP-AF trial, CaCl₂ and NaCl were slowly injected into each GP to avoid
pressure buildup inside the GP. No significant bradycardia (<40 bpm) was noticed in any patient.

medRxiv preprint doi: https://doi.org/10.1101/2023.06.05.23290999; this version posted June 7, 2023. The copyright holder for this preprint

	(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.		
260	Surgery duration (beginning of sternotomy to completion of wound closure) and peri-operative		
261	mortality and morbidity were not different between the two groups (Table 2).		
262	Comparison of POAF initiation between the CAP-AF and CAP-AF2 trial		
263	To understand the mechanism(s) responsible for the contradictory effect of Ca ²⁺ -		
264	mediated autonomic denervation on POAF, we compared the pattern of POAF initiation that was		
265	adjudicated as POAF in the CAP-AF and CAP-AF2 trials. In the CAP-AF2 trial, POAF initiation		
266	was immediately preceded by frequent atrial bigeminy, couplets or nonsustained AT (NSAT, \geq 3		
267	beats) in 33/43 (76.7%; Figure 2A) and 9/31 patients (29.0%) in the CaCl ₂ and NaCl group,		
268	respectively ($P < 0.001$). The most common type of POAF initiation in the NaCl group was sinus		
269	rhythm with a single PAC (16/31 patients, 51.6%; Figure 2B), which only occurred in 6/43		
270	patients (14.0%) in the CaCl ₂ group (P <0.001). On the contrary, in the CAP-AF trial, POAF		
271	initiation was preceded by frequent atrial bigeminy, couplets or NSAT in 11/15 patients (73.3%)		
272	and 22/36 patients (61.1%) in the CaCl ₂ and NaCl group, respectively ($P=0.405$). The second		
273	most common initiation pattern was sinus rhythm with a single PAC that occurred in $3/15$		
274	(20.0%) and 12/36 (33.3%) patients in the CaCl ₂ and NaCl group, respectively ($P=0.341$).		

Immunohistochemical staining of anterior right GP and adjacent atrial myocardium 275

276 Parasympathetic and sympathetic neural elements were marked by ChAT and TH staining, respectively. In the 40 patients not in the CAP-AF or CAP-AF2 trial (n=20 for CABG 277 and n=20 MR surgery), the percentage of area in the anterior right GP stained positive for TH 278 was significantly higher in the CABG group but that stained positive for ChAT was higher in the 279 MV surgery group (Figure 3A-C). The ratio of TH/ChAT was therefore significantly higher in 280 the CABG group. When quantitative analysis of TH and ChAT expressing nerves in the atrial 281 myocardium adjacent to the ARGP was performed, similar results also hold true for nerve 282 283 density (Figure 3D-F) as well as protein expression assessed by ELISA (Figure 3G-I) and

Western blot (**Online Figure 3**). The extent of fibrosis in the atrial myocardium adjacent to the anterior right GP was not different between the two groups (**Online Figure 4**).

286

287 DISCUSSION

The main finding of the CAP-AF2 trial is that Ca^{2+} -mediated autonomic denervation 288 unexpectedly increased the incidence of POAF in patients with MR without persistent AF, 289 contradictory to the results of the CAP-AF trial that only recruited patients receiving isolated 290 CABG. In the CAP-AF2 trial, atrial bigeminy, couplets or NSAT immediately preceded the 291 initiation of POAF in the CaCl₂ group but not the NaCl group. Immunohistochemistry studies 292 demonstrated different autonomic substrates between patients with MR and ischemic heart 293 disease. A lower ratio of TH/ChAT in the anterior right GP and adjacent myocardium in the 294 former suggests parasympathetic dominance at the tissue level; a higher TH/ChAT ratio in the 295 latter suggests sympathetic dominance. Ca²⁺-mediated autonomic denervation therefore exerts 296 contradictory effects on the incidence of POAF on patients receiving MV surgery vs. CABG. 297 Multiple preclinical studies of MR-related AF have demonstrated similar findings.²²⁻²⁷ 298 First, the atrial effective period was prolonged with significant heterogeneity. Second, moderate 299 but heterogeneous interstitial fibrosis existed. Third, atrial conduction velocity was reduced and 300 often heterogeneous. Fourth, inflammatory cell infiltration of atrial myocardium was observed. 301 302 Fifth, malfunction of major metabolic pathways occurred in patients with MR and was further augmented by β -adrenergic stimulation. Improvement of metabolic derangement mitigated AF. 303 Although spontaneous AF was rarely reported by these studies, AF could easily be induced by 304 electrical stimulation, indicating that in the presence of appropriate triggers. AF can be initiated 305 and maintained by the aforementioned AF substrates. In the present study, patients with 306 persistent AF were excluded. The study population therefore represents one in which MR was 307

severe enough that already created a substrate for AF but without appropriate triggers to initiate
AF. Parasympathetic dominance at the tissue level may be protective in patients with severe MR.
Disturbance of the cardiac autonomic balance by Ca⁺⁺-mediate autonomic denervation provided
the triggers to initiate POAF as illustrated in Figure 2A.

In patients with paroxysmal AF without significant structural heart diseases, AF episodes 312 are commonly preceded by co-activation of the sympathetic and parasympathetic nervous 313 systems. ^{10,12,28} However, exaggerated sympathetic activity is the hallmark of AF initiation. In the 314 majority of patients including those with structural heart diseases, AF episodes are usually 315 preceded by an increased low-frequency component of HRV, a marker of sympathetic 316 hyperactivity.²⁸ Preclinical studies on ambulatory animals also indicated that paroxysmal AF and 317 AT were invariably preceded by activation of the intrinsic cardiac ANS evidenced by rapid 318 discharges recorded from the GP and ligament of Marshall.^{11,29} Although the paroxysmal AF or 319 AT episodes were also accompanied by co-activation of the extrinsic cardiac ANS, such as 320 vagus nerve and stellate ganglion, 20-25% of the episodes of paroxysmal AT or AF were not 321 preceded by activation of the vagus nerve or stellate ganglion, indicating that the intrinsic cardiac 322 ANS (e.g. GP) plays an indispensable role in the initiation of paroxysmal AF or AT. Moreover, 323 324 PACs were typically preceded by a surge of sympathetic nerve activity; most of the paroxysmal AF or AT episodes followed a larger and more sustained surge of sympathetic nerve activity.^{11,30} 325 The average activity of the intrinsic cardia ANS, evidenced by direct neural recording of GP, 326 also strongly correlated with the PAC burden in patients after cardiac surgery.³⁰ 327

In the CAP-AF2 trial, POAF was preceded by frequent atrial bigeminy, couplets or NSAT in only 9/31 (29.0%) patients in the NaCl group, in contrast to 33/43 (76.7%) patients in the CaCl₂ group. That is, CaCl₂-mediated autonomic denervation altered the POAF initiation pattern from sinus rhythm with a single PAC to frequent bigeminy, couplets or NSAT, possibly resulting from shifting the sympathetic-parasympathetic balance (**Figure 2**). As discussed before,

333 PACs and paroxysmal AT are often preceded by a surge of sympathetic nerve activity.

334	Immunohistochemistry data revealed parasympathetic dominance at the tissue level (both GP
335	and atrial myocardium) in patients receiving MV surgery. Ca ²⁺ -mediated autonomic denervation
336	likely injured more parasympathetic than sympathetic neural elements, which tipped the balance
337	toward sympathetic dominance. As a result, frequent atrial bigeminy, couplets or NSAT
338	occurred, eventually initiating POAF. Of note, in the CAP-AF trial, Ca ²⁺ -mediated autonomic
339	denervation suppressed PACs and NSAT but did not affect the initiation pattern of POAF. We
340	hypothesize that a higher sympathetic state is also critical in POAF initiation in patients
341	undergoing CABG. Ca ²⁺ -mediated autonomic denervation mitigated higher tissue sympathetic
342	activity, evidence by less frequent complex PACs and NSAT. Additionally, HRV showed
343	diminished HF and LF components but preserved LF/HF ratio, ¹⁹ suggesting that the sympathetic-
344	parasympathetic balance was not perturbed by autonomic denervation thereby not altering the
345	initiation pattern of POAF. Therefore, for patients in the CaCl ₂ group of the CAP-AF trial, if
346	autonomic denervation failed to overcome the higher sympathetic activity, POAF was triggered
347	by similar mechanisms as seen in the NaCl group. Based on the contradictory results in the CAP-
348	AF and CAP-AF2 trials, perturbation of the autonomic balance can be beneficial or harmful,
349	depending on the underlying substrate.

An important lesson learned from the two CAP-AF trials is that autonomic remodeling 350 and perhaps other remodeling processes may vary greatly among different cardiovascular 351 diseases, leading to differential effects on POAF when cardiac ANS is perturbed. If the CAP-352 353 AF2 trial had recruited both MV surgery and CABG populations, the results might have been 354 neural; the harm to the MV surgery population would have not been exposed. Future studies on the pathogenesis or therapies of AF, not limited to POAF, may need to focus on a relatively 355 356 homogeneous population and avoid a study population including multiple cardiovascular diseases. For example, the AFACT³¹ trial randomized patients to surgical PVI vs. surgical 357

PVI+GP ablation and reported no benefit conferred by GP ablation, contradictory to the 358 beneficial effects of GP ablation reported by the largest randomized clinical trial (catheter PVI 359 vs. PVI+GP ablation) that only recruited patients with paroxysmal AF without prior ablation.¹⁶ 360 Notably, in the AFACT trial, 59% patients had persistent AF, 43% patients had severely 361 enlarged left atrium (LA volume index>40 mL/M²), and nearly 25% had prior catheter ablation. 362 The conflicting results from the aforementioned two trials may stem from two distinct study 363 populations. Two recently published trials further exemplified this viewpoint. By injecting 364 botulinum toxin into the major atrial GP as a means of autonomic denervation, reduction of the 365 incidence of POAF was reported in one randomized clinical trial on patients receiving CABG but 366 a neutral effect was reported by the other trial recruiting patients undergoing CABG and/or valve 367 surgery.^{32, 33} 368

369 Study Limitation

First, we did not directly record the neural activity of the GP; the activity of the intrinsic 370 cardiac ANS was therefore deduced from expression of TH and ChAT in the anterior right GP 371 and adjacent myocardium. In addition, the postoperative HRV was inconclusive likely due to a 372 smaller-than-expected sample size resulting from premature termination of the trial. The 373 interpretation that higher sympathetic activity preceded POAF was therefore based on published 374 pre-clinical and clinical studies. Second, we do not have immunohistochemical data on normal 375 controls to compare tissue autonomic innervation among normal controls, patients with MR and 376 patients with ischemic heart disease. Therefore, sympathetic and parasympathetic dominance 377 378 described in this study only represents the comparison between the MR and CABG populations. Third, for logistical reasons, only the anterior right GP and adjacent myocardium were sampled. 379 Tissue autonomic innervation and fibrosis may not be generalized to the entire atrial neural 380 381 network and myocardium. Fourth, only five of 160 patients were found to have paroxysmal AF 382 based on history and 7-day Holter monitoring prior to surgery. The prevalence of paroxysmal AF

383	is probably underestimated. We presume that under-diagnosis of paroxysmal AF would have
384	been evenly distributed by randomization and will not affect the outcome assessment.
385	
386	CONCLUSIONS
387	Unlike patients undergoing CABG, autonomic denervation increased the risk of POAF in
388	patients receiving MV surgery, indicating distinct substrates for POAF in different
389	cardiovascular diseases. This observation may explain conflicting results from published POAF
390	trials that recruited patients undergoing CABG and valvular surgery. While autonomic
391	denervation has emerged as a novel therapy to treat various cardiovascular diseases, it should
392	only be performed with evidence supported by randomized clinical trials.
393	
394	
395	Source of Funding: LiaoNing Revitalization Talents Program: XLYC2001001 (Dr. Huishan
396	Wang)
397	Disclosure: No author has conflict of interest.
398	

400 **REFERENCES:**

- 1. Dobrev D, Aguilar M, Heijman J, Guichard JB, Nattel S. Postoperative atrial fibrillation:
- 402 mechanisms, manifestations and management. Nat Rev Cardiol 2019;16:417-36.
- 403 2. Crystal E, Connolly SJ, Sleik K, Ginger TJ, Yusuf S. Interventions on prevention of
- 404 postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis. Circulation

405 2002;106:75-80.

- 406 3. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial
- fibrillation developed in collaboration with EACTS. Eur Heart J 2016;37:2893-962.
- 408 4. January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update of the 2014
- 409 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of
- 410 the American College of Cardiology/American Heart Association Task Force on Clinical
- 411 Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2019;74:104-32.
- 412 5. Mitchell LB, Exner DV, Wyse DG, et al. Prophylactic Oral Amiodarone for the Prevention of
- 413 Arrhythmias that Begin Early After Revascularization, Valve Replacement, or Repair:
- 414 PAPABEAR: a randomized controlled trial. Jama 2005;294:3093-100.
- 415 6. Ardell JL, Andresen MC, Armour JA, et al. Translational neurocardiology: preclinical models
- 416 and cardioneural integrative aspects. J Physiol 2016;594:3877-909.
- 417 7. Pauza DH, Skripka V, Pauziene N, Stropus R. Morphology, distribution, and variability of the
- 418 epicardiac neural ganglionated subplexuses in the human heart. Anat Rec 2000;259:353-82.
- 419 8. Ardell JL, Armour JA. Neurocardiology: Structure-Based Function. Compr Physiol

420 2016;6:1635-53.

- 421 9. Hou Y, Scherlag BJ, Lin J, et al. Ganglionated plexi modulate extrinsic cardiac autonomic
- 422 nerve input: effects on sinus rate, atrioventricular conduction, refractoriness, and inducibility of
- 423 atrial fibrillation. J Am Coll Cardiol 2007;50:61-8.

- 424 10. Lombardi F, Tarricone D, Tundo F, Colombo F, Belletti S, Fiorentini C. Autonomic nervous
- 425 system and paroxysmal atrial fibrillation: a study based on the analysis of RR interval changes
- 426 before, during and after paroxysmal atrial fibrillation. Eur Heart J 2004;25:1242-8.
- 427 11. Tan AY, Zhou S, Ogawa M, et al. Neural mechanisms of paroxysmal atrial fibrillation and
- 428 paroxysmal atrial tachycardia in ambulatory canines. Circulation 2008;118:916-25.
- 429 12. Bettoni M, Zimmermann M. Autonomic tone variations before the onset of paroxysmal atrial
- 430 fibrillation. Circulation 2002;105:2753-9.
- 431 13. Patterson E, Po SS, Scherlag BJ, Lazzara R. Triggered firing in pulmonary veins initiated by
- 432 in vitro autonomic nerve stimulation. Heart Rhythm 2005;2:624-31.
- 433 14. Patterson E, Lazzara R, Szabo B, et al. Sodium-calcium exchange initiated by the Ca2+
- transient: an arrhythmia trigger within pulmonary veins. J Am Coll Cardiol 2006;47:1196-206.
- 435 15. Po SS, Nakagawa H, Jackman WM. Localization of left atrial ganglionated plexi in patients
- 436 with atrial fibrillation. J Cardiovasc Electrophysiol 2009;20:1186-9.
- 437 16. Katritsis DG, Pokushalov E, Romanov A, et al. Autonomic denervation added to pulmonary
- 438 vein isolation for paroxysmal atrial fibrillation: a randomized clinical trial. J Am Coll Cardiol
- 439 2013;62:2318-25.
- 440 17. Peunova N, Enikolopov G. Amplification of calcium-induced gene transcription by nitric
- 441 oxide in neuronal cells. Nature 1993;364:450-3.
- 18. Arundine M, Tymianski M. Molecular mechanisms of calcium-dependent neurodegeneration
- in excitotoxicity. Cell Calcium 2003;34:325-37.
- 19. Wang H, Zhang Y, Xin F, et al. Calcium-Induced Autonomic Denervation in Patients With
- 445 Post-Operative Atrial Fibrillation. J Am Coll Cardiol 2021;77:57-67.
- 446 20. Zhao J, Zhang Y, Yin Z, et al. Impact of proinflammatory epicardial adipose tissue and
- 447 differentially enhanced autonomic remodeling on human atrial fibrillation. J Thorac Cardiovasc
- 448 Surg 2022.

- 449 21. Wang H, Han J, Wang Z, et al. A prospective randomized trial of the cut-and-sew Maze
- 450 procedure in patients undergoing surgery for rheumatic mitral valve disease. J Thorac
- 451 Cardiovasc Surg 2018;155:608-17.
- 452 22. Everett TH 4th, Verheule S, Wilson EE, Foreman S, Olgin JE. Left atrial dilatation resulting
- 453 from chronic mitral regurgitation decreases spatiotemporal organization of atrial fibrillation in
- left atrium. Am J Physiol Heart Circ Physiol. 2004 Jun;286(6):H2452-60.
- 455 23. Verheule S, Wilson E, Everett T 4th, Shanbhag S, Golden C, Olgin J.Alterations in atrial
- 456 electrophysiology and tissue structure in a canine model of chronic atrial dilatation due to mitral
- 457 regurgitation. Circulation. 2003 May 27;107(20):2615-22.
- 458 24. Everett TH 4th, Wilson EE, Verheule S, Guerra JM, Foreman S, Olgin JE. Structural atrial
- 459 remodeling alters the substrate and spatiotemporal organization of atrial fibrillation: a
- 460 comparison in canine models of structural and electrical atrial remodeling.
- Am J Physiol Heart Circ Physiol. 2006 Dec;291(6):H2911-23.
- 462 25. Tang M, Zhang S, Sun Q, Huang C. Alterations in Electrophysiology and Tissue Structure of
- the Left Atrial Posterior Wall in a Canine Model of Atrial Fibrillation Caused by Chronic Atrial
- 464 Dilatation. Circ J 2007:71:1636-1642.
- 465 26. Monti LD, Lucotti PC, Setola E et al. Effects of chronic elevation of atrial natriuretic peptide
- and free fatty acid levels in the induction of type 2 diabetes mellitus and insulin resistance in
- 467 patients with mitral valve disease. Nutr Metab Cardiovasc Dis. 2012 Jan;22(1):58-65.
- 468 27. Oikawa S, Kai Y, Mano A, et al. Non-neuronal cardiac acetylcholine system playing
- indispensable roles in cardiac homeostasis confers resiliency to the heart. J Physiol Sci. 2021 Jan
- 470 18;71(1):2.

- 471 28. Carnagarin R, Kiuchi MG, Ho JK, Matthews VB, Schlaich MP. Sympathetic Nervous
- 472 System Activation and Its Modulation: Role in Atrial Fibrillation. Front Neurosci 2018;12:1058.
- 473 29. Choi EK, Shen MJ, Han S, et al. Intrinsic cardiac nerve activity and paroxysmal atrial
- tachyarrhythmia in ambulatory dogs. Circulation 2010;121:2615-23.
- 475 30. Shen MJ, Coffey AC, Straka S, et al. Simultaneous recordings of intrinsic cardiac nerve
- 476 activity and skin sympathetic nerve activity from human patients during the postoperative period.
- 477 Heart Rhythm 2017;14:1587-93.
- 478 31. Driessen AHG, Berger WR, Krul APJ, van den Berg NWE, Neefs J, Piersma FR, Yin
- 479 DRPPCP², de Jong JSSG³, van Boven WP, de Groot JR[•] Ganglion Plexus Ablation in Advanced
- 480 Atrial Fibrillation: The AFACT Study. J Am Coll Cardiol. 2016 Sep 13;68(11):1155-1165.
- 481 32. Pokushalov E, Kozlov B, Romanov A, et al. Botulinum toxin injection in epicardial fat pads
- 482 can prevent recurrences of atrial fibrillation after cardiac surgery: results of a randomized pilot
- 483 study. J Am Coll Cardiol 2014;64:628-9.
- 484 33. Waldron NH, Cooter M, Haney JC, et al. Temporary autonomic modulation with botulinum
- toxin type A to reduce atrial fibrillation after cardiac surgery. Heart Rhythm 2019;16:178-84.

487 FIGURE LEGENDS

488	Figure 1. Trial design and primary outcome. A. Flow diagram of trial design. A total of 884	
489	patients were screened. Up to the midterm analysis, 160 patients consented to participate.	
490	Participants were 1:1 randomized to CaCl ₂ injection and NaCl injection. B. Cumulative	
491	incidence of POAF over 7 days after surgery. C. Kaplan-Meier curve of POAF. HR: hazard	
492	ratio. CI: 95% confidence interval.	
493		
494	Figure 2. The most common pattern of POAF initiation in the CAP-AF2 trial. A. POAF was	
495	preceded by frequent atrial bigeminy, couplets or nonsustained AT in the $CaCl_2$ group B. A	
496	single PAC (red arrow) initiated POAF in the NaCl group.	
497		
498	Figure 3. Tissue autonomic innervation. Tissue samples obtained from patients undergoing	
499	coronary artery bypass surgery (CABG, n=20) or mitral valve surgery (MVS, n=20) for mitral	
500	regurgitation. A-C. Percentage of the area in the anterior right ganglionated plexi stained	
501	positive for choline acetyltransferase (ChAT; A) or tyrosine hydroxylase (TH, B) as well as the	
502	TH/ChAT ratio (C). D-F. ChAT staining, TH staining and TH/ChAT ratio of autonomic nerves.	
503	G-I. Quantitative analysis by ELISA of TH and ChAT expression. D-I. Tissue samples obtained	
504	from atrial myocardium adjacent to the anterior right ganglionated plexi. GP. *: $p < 0.05$; **:	

505 *p*<0.01; ***: *p*<0.001.

507

508

Table 1. Demographic and Clinical Characteristics at Baseline

	CaCl ₂ (n=78)	NaCl (n=82)	Р
Age, yrs	60 (56, 63)	61 (53.25, 66)	0.652
Female, n (%) *	32 (41.03)	38 (46.34)	0.498
Hypertension, n (%) *	33 (42.31)	25 (30.49)	0.120
Diabetes, n (%) *	9 (11.54)	5 (6.1)	0.223
paroxysmal AF, n (%) *	3 (3.85)	2 (2.44)	0.955
CHA ₂ DS ₂ -VASc score	1 (0,2)	1 (1,2)	0.235
CAD, n (%) *	18 (23.08)	12 (14.63)	0.171
EF, %	57 (55, 60)	58 (56, 60)	0.167
FS, %	30 (28, 32)	30 (29, 32)	0.093
Left atrium, mm	44 (40, 48)	42 (38, 46.25)	0.084
On β -blocker, n (%)	31 (39.7%)	28 (34.2%)	0.463
Average HR, beats/min	74 (69.5, 80)	75 (70, 82)	0.323
Highest HR, beats/min	117 (109, 127)	118 (110, 130)	0.227
Lowest HR, beats/min	51 (48, 57)	54 (49, 59)	0.069
hsCRP, mg/l	0.25 (0.25, 3.1)	0.61 (0.25,1.75)	0.788
IL6, pg/l	3.08 (1.87, 6.68)	2.73 (1.85, 4.88)	0.838
BNP, pg/l	461.6 (107.9, 1622)	223.2 (107.7, 764.32)	0.850
ALT, U/1	19.7 (14.32, 26.65)	17.2 (13.51, 27.56)	0.390
AST, U/l	19.76 (15.35, 26.24)	19.04 (16.74, 26.51)	0.738
Creatinine, mmol/l	74.11 (62.61, 83.5)	67.98 (60.83, 81.46)	0.348
Heart rate variability			
pNN50, %	3.35(1.42, 9)	3.25(0.9, 9.75)	0.391
rMSSD, ms	19.5(15.83, 29.4)	19.85(13.83, 31.1)	0.941
SDNN, ms	55.2 (45.7, 64.15)	55.3 (42.1, 66.22)	0.927
Premature atrial beats			
Single, %	0.07 (0.02, 0.27)	0.1 (0.02, 0.27)	0.819
Couplets, 10^{-2} .%	0.23 (0.04, 0.87)	0.22 (0.05, 0.86)	0.988
NSAT, 10 ⁻² .%	0.11 (0.03, 0.47)	0.19 (0.03, 0.62)	0.380

Values are median (1st, 3rd quartile), or n (percentage). AF= atrial fibrillation; ALT = alanine
transaminase; AST = aspartate transaminase; BNP = brain natriuretic peptide; CAD: coronary
artery disease; EF = ejection fraction; FS = Fraction shortening; COPD = chronic obstructive
pulmonary disease; hsCRP = high-sensitivity C-reaction protein; IL-6 = interleukin-6; MI =
history of myocardial infarction; pNN50 =percentage of RR intervals that differ by >50 ms;

rMSSD =root-mean-square of successive RR interval difference; SDNN = SD of normal-to-

normal interval; NSAT=non-sustained atrial tachyarrhythmia. *: Calculated by chi-square test.

516 Others: calculated by Mann-Whitney *U* test.

518

Table 2. Secondary outcomes and peri-operative conditions

	$CaCl_2$ (n=78)	NaCl (n=82)	р
ICU stay, hours	24 (21, 37.25)	23 (20, 37.75)	0.799
Hospitalization, days	8 (7, 9)	8 (7, 9)	0.317
Hospitalization $>$ 7 days, n (%) *	30 (69.8)	14 (45.2)	0.033
AF burden, %	2.01 (0, 25.07)	0 (0, 10.24)	0.066
Number of AF episodes in patient	1 (0, 4)	0 (0, 1)	0.007
Average ventricular rate in AF	103 (87, 127)	108 (94, 125)	0.349
Patients with AF >48h, n (%) *	11 (14.10)	10 (12.20)	0.721
Patients with AF >24h, n (%) $*$	19 (24.36)	12 (14.63)	0.120
Inflammatory markers			
hs-CRP (POD1), mg/L	41.78 (16.83, 60.02)	37.16 (23.57, 68.7)	0.444
IL6 (POD1), pg/L	89.60 (63.90, 131.83)	95.25 (58.62,130.35)	0.661
Hs-CRP (POD3), mg/L	119.47 (83.04, 169.62)	122.62 (82.51, 178.97)	0.500
IL6 (POD3), pg/L	62.94 (41.39, 99.46)	71.72 (39.13, 103.67)	0.965
Amiodarone, n (%) *			0.039
0	63 (80.77)	75 (91.46)	
0-2500 mg	10 (12.82)	7 (8.54)	
>2500 mg	5 (6.41)	0 (0)	
Esmolol, n (%) *			0.873
0	53 (67.95)	55 (67.07)	
0-600 mg	5 (6.41)	7 (8.54)	
>600 mg	20 (25.64)	20 (24.39)	
Cardioversion, n (%) †	2 (2.56)	2 (2.44)	>0.999
Major surgery time, min	111 (90, 137)	116 (91, 145)	0.565
Surgery type, n (%) *			
MV repair	36 (46.16)	45 (54.88)	0.270
MV replacement	42 (53.85)	37 (45.12)	
MV replacement, n (%) *			
Mechanical valve	28 (66.67)	26 (70.27)	0.731
Tissue valve	14 (33.33)	11 (29.73)	
Death, n (%)	0	0	-
Post-operative EF, %	56 (53, 58)	57 (55, 59)	0.222
Troponin-T, ng/L	380(260.25, 559.75)	333.5(243.75, 490.25)	0.131
Poor wound healing, n (%)	0	0	-
Procalcitonin (POD3), ng/mL	0.14(0.11, 0.17)	0.13(0.10, 0.15)	0.083
Pleural effusion, n (%) †	1 (1.28)	4 (4.88)	0.368
On ventilator >96 h, n (%) \dagger	1 (1.28)	0	0.487
Average heart rate (bpm)	85 (79, 91)	85 (76, 93)	0.768
Renal dysfunction, n (%) †	1 (1.28)	0	0.487
Post-operative myocardial	[°]	0	
infarction, %	U	U	-
Stroke, %	0	0	-

519 Values are median (1st, 3rd quartile) or n (percentage). POD: postoperative day. All

520 abbreviations identical to Table 1. *Calculated by chi-square test. †Calculated by Fisher exact

521 test. Others: calculated by Mann-Whitney *U* test.

- 523 Figure 1. Trial design and primary outcome. A. Flow diagram of trial design. A total of 884
- 524 patients were screened. Up to the midterm analysis, 160 patients consented to participate.
- 525 Participants were 1:1 randomized to CaCl₂ injection and NaCl injection. **B.** Cumulative
- 526 incidence of POAF over 7 days after surgery. C. Kaplan-Meier curve of POAF. HR: hazard
- 527 ratio. CI: 95% confidence interval.



529

Figure 1B.



Figure 1C.



- 533 Figure 2. The most common pattern of POAF initiation in the CAP-AF2 trial. A. POAF was
- 534 preceded by frequent atrial bigeminy, couplets or nonsustained AT in the CaCl₂ group **B.** A
- single PAC (red arrow) initiated POAF in the NaCl group.



POAF

Figure 2B.



537

- 539 Figure 3. Tissue autonomic innervation. Tissue samples obtained from patients undergoing
- 540 coronary artery bypass surgery (CABG, n=20) or mitral valve surgery (MVS, n=20) for mitral
- 541 regurgitation. A-C. Percentage of the area in the anterior right ganglionated plexi stained
- 542 positive for choline acetyltransferase (ChAT; A) or tyrosine hydroxylase (TH, B) as well as the
- 543 TH/ChAT ratio (C). **D-F.** ChAT staining, TH staining and TH/ChAT ratio of autonomic nerves.
- 544 G-I. Quantitative analysis by ELISA of TH and ChAT expression. D-I. Tissue samples obtained
- from atrial myocardium adjacent to the anterior right ganglionated plexi. GP. *: p < 0.05; **:
- 546 *p*<0.01; ***: *p*<0.001.

Figure 3.



